CCL25 promotes progression of nonalchoholic fatty liver disease via macrophages activation
AASLD LiverLearning®, Jingmin Zhao, 195586
Rapid Decrease of Intracellular Water Predicts Short-term Efficacy of Vasopressin Type 2 Receptor Antagonism in Decompensated Cirrhosis for Refractory Ascites
AASLD LiverLearning®, Shunsuke Shiba, 195331
Hepatic CD36 expression and traslocation to the plasma membrane are increased under hypoxic conditions
AASLD LiverLearning®, Carmelo García-Monzón, 195587
Cost-effectiveness of Transjugular Intrahepatic Portosystemic Shunt (TIPS) insertion compared to serial large volume paracentesis (LVP) in recurrent ascites
AASLD LiverLearning®, Nicole Shen, 195332
Transferrin and ceruloplasmin kinetics discriminate simple steatosis from nonalcoholic steatohepatitis.
AASLD LiverLearning®, Arthur McCullough, 195588
A Randomized Controlled Study to Compare Efficacy of Terlipressin 6 mg/day and Terlipressin 4 mg/day in Patients with Hepatorenal Syndrome
AASLD LiverLearning®, Hyung Joon Yim, 195333
VEGFR3 dependent lymphangiogenesis regulates the progression of liver fibrosis in a mouse model of NASH.
AASLD LiverLearning®, Matthew Burchill, 195589
Inhibition of NADPH Oxidase in Phagocytes Improves Hepatic Steatosis, Inflammation and Fibrosis in a Mouse Model of Severe Nonalcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Lucy Golden-Mason, 195602
Alcoholic liver disease is associated with improved outcomes after TIPS performed for refractory ascites and hepatic hydrothorax
AASLD LiverLearning®, Vilas Patwardhan, 195347
Identification of circulating microRNAs altered by an Apoptosis Signal-Regulating Kinase 1 (ASK1) inhibitor in a Fast Food Diet NAFLD mouse model
AASLD LiverLearning®, Nandita Sarkar, 195603
Early paracentesis is associated with lower mortality and shorter length of stay in hospitalized cirrhotics with and without spontaneous bacterial peritonitis in a multi-year national inpatient sample.
AASLD LiverLearning®, Arun Jesudian, 195348
Dietary cholesterol triggers liver fibrosis and a tissue-remodeling and lipid-metabolizing phenotype in Kupffer Cells in a murine model of NAFLD
AASLD LiverLearning®, Brett McGettigan, 195604
Benefit of Supplemental Nutrition Education for Severely Malnourished Cirrhotic Patients
AASLD LiverLearning®, Amanda Chaney, 195349
The utility of the serum C16:1n7/C16:0 ratio as a diagnostic marker of non-alcoholic steatohepatitis
AASLD LiverLearning®, Kazutoshi Yamada, 195605
Collagen turnover biomarkers distinguish healthy from NAFLD patients and aid identification of patients with evidence of histologically active NASH
AASLD LiverLearning®, Saurabh Gupta, 195618
Stromal Sulfatase-2 - a critical regulator of hepatocellular carcinoma growth and migration.
AASLD LiverLearning®, Marco Zaki, 195363
Oxidized mtDNA induced steatohepatitis through cGAS signaling pathway
AASLD LiverLearning®, Wajahat Mehal, 195619
Differential Notch Signaling Modulates Experimental Hepatic Carcinogenesis in Mice
AASLD LiverLearning®, Yasuhiro Nakano, 195364
Non-alcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor
AASLD LiverLearning®, Jittima Weerachayaphorn, 195620
NPR-C Accelerates Obesity Induced NASH and Potentiates the Development of HCC
AASLD LiverLearning®, Prasanna Santhekadur, 195365
Phosphoproteomics analysis of animal models of nonalcoholic fatty liver disease reveals that interactions between diet and environmental chemicals regulate hepatic nuclear receptor protein levels and phosphorylation status
AASLD LiverLearning®, Josiah Hardesty, 195621
Establishment of Hepatocellular Carcinoma derived from a cancer stem cell line is characterized by significant metabolic reprogramming
AASLD LiverLearning®, Shamir Cassim, 195379
Controlled Attenuation Parameter (CAP) diagnostic performance in Vibration Controlled Transient Elastography (Fibroscan®) for steatosis staging in comparison to direct quantification through digital morphometric analysis of liver biopsy
AASLD LiverLearning®, Leandro Mendes, 195635
DPP4 Inhibitor Suppressed Progression of NASH-related Hepatocellular Carcinoma with Inhibition of Metabolic Reprograming in p62-Keap1-Nrf2-Pentose Phosphate Pathway in a Mouse Model: A Metabolomic Analysis
AASLD LiverLearning®, Takumi Kawaguchi, 195380
Elastogram quality in Vibration Controlled Transient Elastography: implications for Controlled Attenuation Parameter steatosis grading compared to digital morphometric analysis of liver biopsy.
AASLD LiverLearning®, Leandro Mendes, 195636
Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating natural killer cell chemotaxis in mice
AASLD LiverLearning®, Sohji Nishina, 195381
Dietary counselling focusing only on fructose consumption improves hepatic inflammation in patients with NAFLD - a prospective, controlled, randomized open-label study (NUCES NASH)
AASLD LiverLearning®, Jorn Schattenberg, 195637
Baseline Serum Pro-C3 Predicts Response to BMS-986036 (peg-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Manal Abdelmalek, 195650
Identification of long non-coding RNAs that serve as therapeutic targets for Hepatocellular Carcinoma
AASLD LiverLearning®, Bruno Sangro, 195395
Effective Biomarkers for advance fibrosis NASH and reflect biomarkers as changes of liver fibrosis with NASH
AASLD LiverLearning®, Miwa Kawanaka, 195651
Hepatitis C virus (HCV) mimics effects of Glypican-3 (GPC3) on CD81 and promotes development of hepatocellular carcinomas via activation of Hippo pathway in normal hepatocytes.
AASLD LiverLearning®, Yuhua Xue, 195396
Burden of Illness Economic Model for Patients with Non-alcoholic Steatohepatitis (NASH) in the United States
AASLD LiverLearning®, Zobair Younossi, 195652
Mechanisms of Selective Deletion of MYCN+CD133+ Liver Cancer Stem Cells by Acyclic Retinoid via Induction of Nuclear Transglutaminase 2
AASLD LiverLearning®, Soichi Kojima, 195397
Dysregulated Expression of the Long non-coding RNA (lncRNA) MALAT1 in the Liver of Patients with Nonalcoholic fatty liver Disease (NAFLD) Stratifies Patients into the Histological Phenotypes Associated with the Disease Severity
AASLD LiverLearning®, Silvia Sookoian, 195653
Liver function tests do not predict liver damage in diabetes. Analysis of liver steatosis and fibrosis by transient elastography in routine diabetes care
AASLD LiverLearning®, Rosa Lombardi, 195666
Clinical application of the electronic medical record-based 'alert ordering system', designed to prevent hepatitis B virus reactivation in patients receiving systematic chemotherapy or immunosuppressive therapy.
AASLD LiverLearning®, Takako Inoue, 195411
A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study
AASLD LiverLearning®, Michelle Long, 195667
Minimal increases of alpha-fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: a 8-year longitudinal cohort study in 262 patients - final results
AASLD LiverLearning®, Pietro Lampertico, 195412
One Carbon Cycle Disturbances in Kwashiorkor; a Childhood Syndrome of Malnutrition and Hepatic Steatosis
AASLD LiverLearning®, Thaddaeus May, 195668
HBsAg and HBcrAg concentrations differ between genotype A1 and A2 HBeAg negative patients with chronic hepatitis B: complexity within sub-genotypes has implications for newer therapy paradigms
AASLD LiverLearning®, Ivana Carey, 195413
Liver fibrosis as assessed by the FIB-4 index and metabolic markers in subjects with type 2 Diabetes
AASLD LiverLearning®, Claudia Filozof, 195669
High dietary acid load is associated with non-alcoholic fatty liver disease (NAFLD) in a large population-based study: The Rotterdam Study
AASLD LiverLearning®, L.J.M. Alferink, 195682
Effectiveness of a Statewide Hepatitis B Virus (HBV) Vaccination Program in Preventing Symptomatic HBV Infection Among Alaska Native (AN) Persons, Alaska 1987-2011
AASLD LiverLearning®, Prabhu Gounder, 195427
Severity of Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Morbidity and All-Cause Mortality Among Patients Undergoing Weight Loss Surgery
AASLD LiverLearning®, Suzanne Sharpton, 195683
High Prevalence of Naturally Occurring HBV Variants Across HBV Phenotypes and Genotypes in Racially Diverse Patients with Chronic Hepatitis B in the United States and Canada
AASLD LiverLearning®, Daryl Lau, 195428
Serum Wisteria floribunda agglutinin-positive Mac-2-binding Protein Levels Predict the Presence of Fibrotic Nonalcoholic Steatohepatitis (NASH) and NASH Cirrhosis
AASLD LiverLearning®, Naim Alkhouri, 195684
Critical role of B cell lineage in dictating response and non-response to hepatitis B vaccine; A retrospective and prospective study with healthy adults
AASLD LiverLearning®, Hiroyoshi Doi, 195429
Clinical and histological characteristics of nonalcoholic fatty liver disease in Japanese non-obese patients
AASLD LiverLearning®, Toshihide Shima, 195698
Feasibility of strategic monitoring in patients with prior HBV exposure undergoing anti-CD20 monoclonal antibody therapy: a prospective observational study
AASLD LiverLearning®, Wai-Kay Seto, 195443
Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven nonalcoholic fatty liver disease
AASLD LiverLearning®, Won Kim, 195699
Can Quantitative HBsAg Threshold Predict High Viral Load and Risk of Mother to Child Transmission? Like Life, You Get What You Pay For
AASLD LiverLearning®, Cynthuja Thilakanathan, 195444
Long-Term Outcomes of Diabetic Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Zobair Younossi, 195700
ALT Flares are Associated with Increased Rates of HBeAg Seroconversion and HBV DNA Decline in Chronic Hepatitis B Infection: A Longitudinal Cohort Study from the Hepatitis B Research Network (HBRN)
AASLD LiverLearning®, Mayur Brahmania, 195445
Low serum concentration of carotenoids is associated with non-alcoholic fatty liver disease (NAFLD)
AASLD LiverLearning®, James Esteban, 195714
Risk of hepatitis B virus (HBV) infection and re-activation after discontinuation of tenofovir and/or lamivudine as part of antiretroviral therapy in a high HBV endemicity setting
AASLD LiverLearning®, Anna Geretti, 195459
Parent Metabolic Risk Factors Are Associated With Concurrent Nonalcoholic Fatty Liver Disease In Adolescent Offspring
AASLD LiverLearning®, Oyekoya Ayonrinde, 195715
Linkage to Care for Alaska Native Persons with Chronic Hepatitis B Virus
AASLD LiverLearning®, Brian McMahon, 195460
NGM282 Significantly Reduces Hepatic Steatosis Independent of Baseline Patient Characteristics and Highly Correlates with Markers of FGFR4 Target Engagement: Results from a Phase 2 Trial in Biopsy-Confirmed NASH Patients
AASLD LiverLearning®, Rohit Loomba, 195716
Comparative effectiveness of prophylactic strategies for perinatal transmission of hepatitis B virus: a network meta-analysis of randomized controlled trials
AASLD LiverLearning®, Gang Qin, 195461
Clinical performance of a new automated assay for the detection of total antibodies against the Hepatitis Delta Virus
AASLD LiverLearning®, Antonella Olivero, 195474
Combination of HBsAg composition and a common TLR3 polymorphism increases prediction of serologic response during treatment with nucleos(t)ide analogues
AASLD LiverLearning®, Janett Fischer, 195475
HBV Knowledge, Screening & Linkage to Care in a Diverse Suburban New Jersey Community: Novel Strategies in a Primary Care Setting
AASLD LiverLearning®, Su Wang, 195476
FIB-4, not APRI predicts the regression of fibrosis in chronic hepatitis B patients treated with nucleos(t)ide analogs.
AASLD LiverLearning®, Devika Kapuria, 195477
Hyperuricemia is independently associated with nonalcoholic fatty liver disease in the United States
AASLD LiverLearning®, Karn Wijarnpreecha, 195733
Looking to the Pancreas: Nonalcoholic Fatty Pancreas Disease is a Predictor of Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Amit Mehta, 195734
Under Utilization of Liver Ultrasound and Biopsy to Diagnose Nonalcoholic Fatty Liver Disease in Patients with Type-2 Diabetes.
AASLD LiverLearning®, Amandeep Singh, 195735
Use of numerical modeling analysis to obtain free cortisol secretion and elimination in patients with cirrhosis: Relationship to liver disease variables
AASLD LiverLearning®, Thierry Thevenot, 195490
Human amniotic epithelial stem cells as a new therapeutic option for portal hypertension and cirrhosis.
AASLD LiverLearning®, Anabel Fernandez-Iglesias, 195491
13C-Methacetin Breath Test detects early clinically significant improvement in liver function after achieving SVR in cirrhotic HCV patients when compared to HVPG and liver stiffness
AASLD LiverLearning®, Jaime Bosch, 195492
Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis
AASLD LiverLearning®, Christos Triantos, 195493
Steatohepatitis and Advanced Fibrosis in NAFLD Patients with Normal Aminotransferases Levels: Prevalence and Clinical features
AASLD LiverLearning®, Naga Chalasani, 195749
Fibrotic burden in non-alcoholic fatty liver disease independently predicts the chronic kidney disease incidence: A large prospective cohort study
AASLD LiverLearning®, Young Eun Chon, 195750
Improvements of Hepatic Fibrosis and Hepatic Collagen Deposition in Non-Alcoholic Steatohepatitis (NASH) Treated with Selonsertib are Associated with Improvement of Patient-Reported Outcomes (PROs)
AASLD LiverLearning®, Zobair Younossi, 195751
Suppression of DNase II activity in fatty livers contributes to induction of RIP1-dependent hepatocyte necrosis through TLR9-IFNβ pathway.
AASLD LiverLearning®, Yoshinobu Saito, 195506
Differential Effects of Hepatic DGAT2 or DGAT1 Knockdown on Steatosis and the Metabolic Flux of Exogenously Administered D5-glycerol or 13C18 -oleic acid into VLDL-TG
AASLD LiverLearning®, Jianshen Qi, 195507
β-Oxidation is Decreased in Non-Alcoholic Fatty Liver Disease: A Non-invasive Assessment Utilizing Palmitate and Acetate Breath Tests
AASLD LiverLearning®, Gihan Naguib, 195508
MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
AASLD LiverLearning®, Rebecca Taub, 195509
Metabolomics approach addresses the heterogeneity of NAFLD and determines subtypes associated with different metabolic alterations
AASLD LiverLearning®, Jose Mato, 195765
Comparison of Sonic Hedgehog and keratin 8/18 immunostains as markers of ballooned hepatocytes in non-alcoholic fatty liver disease (NAFLD)
AASLD LiverLearning®, Dina Tiniakos, 195766
Serum Pro-C3 (N-terminal propeptide of type III procollagen) is associated with hepatic steatosis and fibrosis and responsive to changes in steatosis in patients with NASH
AASLD LiverLearning®, Michael Charlton, 195767
Preclinical analysis of liver-targeted, mild mitochondrial protonophores for treatment of non-alcoholic fatty liver disease and steatohepatitis
AASLD LiverLearning®, Magnus Hansson, 195522
B-hydroxybutyrate protects from alcoholic hepatitis via a Hcar2-cAMP dependent pathway
AASLD LiverLearning®, Wajahat Mehal, 195523
DEPTOR overexpression improves glucose tolerance and lipid metabolism in obese mice
AASLD LiverLearning®, Cristina Bosoi, 195525
Neutrophil Extracellular Traps (NETs) regulate monocyte infiltration and development of HCC in murine NASH
AASLD LiverLearning®, Dirk van der Windt, 195538
High fat diet-induced hepatic transcription and enhancer activity changes are reversed by weight loss in mice
AASLD LiverLearning®, Lyuba Varticovski, 195539
Hepatocyte high-mobility group box 1 (HMGB1) protects against hepatic steatosis
AASLD LiverLearning®, Minjie Lin, 195541
A novel ASBT inhibitor, Benzamide Derivative IMB17-15 repressed NAFLD development in high fat diet-fed Syrian golden hamster
AASLD LiverLearning®, Yucheng Wang, 195554
Pharmacological inhibition of ASBT-mediated intestinal reuptake of bile acids promotes hepatic expansion of regulatory T cells in murine sclerosing cholangitis
AASLD LiverLearning®, Ramesh Kudira, 195299
PBI-4050 Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metabolic Syndrome
AASLD LiverLearning®, Brigitte Grouix, 195555
CCL4-induced cirrhosis and aging differentially modulate spingosine-1 phosphate receptors and sphingosine kinases in the brain
AASLD LiverLearning®, Yunzhou Li, 195300
PBI-4547 Reverses Liver Steatosis and Fibrosis, and Improves Metabolic Syndrome in ob/ob Mice
AASLD LiverLearning®, Brigitte Grouix, 195556
The Apelin/Apelin receptor axis promotes biliary proliferation and liver fibrosis during biliary cholestasis
AASLD LiverLearning®, Marinda Scrushy, 195301
PPARα interplays with CYP2A5 to protect against fatty liver disease
AASLD LiverLearning®, Yongke Lu, 195557
Inhibition of fibrosis and inflammation by a soluble guanylate cyclase stimulator in models of liver disease
AASLD LiverLearning®, Katherine Hall, 195570
A novel TIPS-controlled expansion stent for the treatment of severe portal hypertension. A single center experience.
AASLD LiverLearning®, Ioannis Petridis, 195315
Different Fecal and Blood Microbiota Profiles in Obese Versus Lean Nonalcoholic Fatty Liver Disease
AASLD LiverLearning®, Hwi Young Kim, 195571
Frailty index is a strong predictor of both in-hospital outcomes and after-discharge mortality in cirrhotic patients.
AASLD LiverLearning®, Gaia Caccamo, 195316
Lipopolysaccharide increases the release of CXCL5 in an ex-vivo model for human non-alcoholic fatty liver disease
AASLD LiverLearning®, Olivier Govaere, 195572
Fractional Excretion Of Urea Is A Simple Tool To Aid The Differential Diagnosis of Acute Kidney Injury in Advanced Liver Disease
AASLD LiverLearning®, Kavish Patidar, 195317
MALDI Imaging and High Resolution Mass Spectrometry as a Lipidomic Approach to Assess Nonalcoholic Fatty Liver Disease Pathophysiology and Biomarkers
AASLD LiverLearning®, Pierre Bedossa, 195573